If you liked this article you might like

Trade-Ideas: CytRx (CYTR) Is Today's Weak On High Relative Volume Stock
CytRx Sarcoma Drug Flops in Late-Stage Clinical Trial
Biotech Stock Mailbag: Why Intrexon CEO R.J. Kirk Should Not Be Trusted
CytRx Bear Thesis Explained: Why Sarcoma Drug Trial Will Fail